![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic, inflammatory disorder leading to disability and reduced quality of life. Effective treatment is a significant economic burden on the Italian healthcare system. Economic models in RA are commonly based on indirect treatment comparisons.
Methods: This study assessed the cost–effectiveness of abatacept relative to adalimumab for RA in Italy based on a head-to-head trial by means of a cost–consequence analysis.
Results: Health benefits based on the most stringent efficacy criteria were in favor of abatacept compared to adalimumab. Rates for more costly adverse events were higher for adalimumab compared to abatacept, which was reflected in the lower costs for abatacept (-€237,246 or -€237per patient).
Conclusion: The health economic value of abatacept compared with adalimumab from the perspective of the Italian NHS depends on the choice of health outcome. Health gains with abatacept were generally based on more stringent criteria and lower total costs.
Acknowledgements
The authors would like to thank Michel Peters of Mapi for his assistance with the writing of the manuscript.
Financial & competing interests disclosure
This study was sponsored by Bristol-Myers Squibb. J Sabater and C Nappi are employees of BMS. J Gaultney and K Sion have served as consultants to BMS and have received research funding from BMS. S Iannazzo and M Benucci received a consulting fee from MAPI BV to support the study. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
